Total submissions: 4
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| LDLR- |
RCV000238521 | SCV000294885 | likely pathogenic | Hypercholesterolemia, familial, 1 | 2016-03-25 | criteria provided, single submitter | literature only | |
| Institute of Human Genetics, |
RCV000238521 | SCV001934455 | likely pathogenic | Hypercholesterolemia, familial, 1 | 2021-02-24 | criteria provided, single submitter | clinical testing | |
| Ambry Genetics | RCV002374395 | SCV002667309 | pathogenic | Cardiovascular phenotype | 2021-04-29 | criteria provided, single submitter | clinical testing | The p.D224V pathogenic mutation (also known as c.671A>T), located in coding exon 4 of the LDLR gene, results from an A to T substitution at nucleotide position 671. The aspartic acid at codon 224 is replaced by valine, an amino acid with highly dissimilar properties. This alteration (with legacy nomenclature p.D203V) has been described in subjects with familial hypercholesterolemia (FH) (Giesel J et al. Hum Genet, 1995 Sep;96:301-4; Fouchier SW et al. Hum Genet, 2001 Dec;109:602-15; Nauck MS et al. Hum Mutat, 2001 Aug;18:165-6; Durst R et al. Atherosclerosis, 2006 Dec;189:443-50). Functional studies suggest this alteration causes reduced LDLR activity (Deng SJ et al. J Lipid Res, 2019 03;60:516-527). In addition, this mutation is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). Based on internal structural analysis, this alteration is expected to have a deleterious impact on a residue in the conserved cluster of acidic amino acids at the C-terminal end of LDLR class A repeat 5 (Jeon H and Blacklow C. Annu. Rev. Biochem. 2005;74:535-62; Pedersen NB et al. J Biol Chem, 2014 Jun;289:17312-24; Ambry internal data). Other alterations affecting the same amino acid, p.D224G and p.D224N, have also been reported in association with FH (Loubser O et al. Clin. Genet., 1999 May;55:340-5; Hobbs HH et al. Hum. Mutat., 1992;1:445-66). Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation. |
| Laboratorium voor Moleculaire Diagnostiek Experimentele Vasculaire Geneeskunde, |
RCV000238521 | SCV000606194 | pathogenic | Hypercholesterolemia, familial, 1 | no assertion criteria provided | research |